Heartflow, Inc. HTFL R2KR3KPHARMA
Company Overview
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
Why Investors Should Care
Revenue has grown at a 42.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $176.03M (+39.9% YoY); net profit $-116.79M.
- Trailing 12 Months Year-on-year growth — revenue +41.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 42.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 42.10% |
| 1 Year: | 41.30% |
Stock Price Performance
| 1 Year: | +47.14% |
| 6 Months: | +112.84% |
| 3 Months: | +74.06% |
| 1 Month: | +79.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)73.42 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 42.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HTFL Heartflow, Inc. R2KR3KPHARMA | 48.91 | -15.83 | $4.22B | 0.00% | -20.20% | -135.31% | 42.10% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 31.05M | 32.93M | 37.20M | 43.42M | 46.28M | 52.59M |
| Gross Profit | - | 23.84M | 24.94M | 27.94M | 32.78M | 35.41M | 42.16M |
| Operating Income | - | -14.18M | -14.93M | -17.50M | -13.71M | -15.10M | -29.50M |
| Net Income | -20.93M | -23.38M | -19.14M | -32.34M | -9.20M | -50.85M | -27.38M |
| Diluted EPS | - | -4.66 | -3.43 | -5.25 | -1.46 | -1.04 | -0.32 |
| R&D Expense | - | 9.93M | 11.86M | 13.92M | 15.03M | 17.30M | 21.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 87.17M | 125.81M | 176.03M |
| Gross Profit | 58.05M | 94.45M | 135.20M |
| Operating Income | -72.91M | -61.22M | -64.07M |
| Net Income | -95.66M | -96.43M | -116.79M |
| Diluted EPS | -25.32 | -17.98 | -3.17 |
| R&D Expense | 35.85M | 43.52M | 64.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 118.70M | 359.45M |
| Total Equity | -693.64M | -777.56M | -859.48M | 300.65M |
| Cash & Equivalents | - | 122.77M | 51.37M | 44.78M |
| Total Liabilities | - | - | 209.62M | 58.80M |
| Current Liabilities | - | - | 33.60M | 42.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -76.43M | -69.00M | -54.02M |
| Investing Cash Flow | -6.11M | -4.36M | -238.57M |
| Financing Cash Flow | 169.32M | 2.24M | 286.04M |
| Capital Expenditure | -6.11M | -4.36M | -5.03M |
| Free Cash Flow | -82.54M | -73.36M | -59.05M |
| Share Buybacks | 228.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 66.6% | 75.1% | 76.8% |
| Operating Margin % | -83.6% | -48.7% | -36.4% |
| Net Margin % | -109.7% | -76.6% | -66.3% |
| ROE % | 12.3% | 11.2% | -38.8% |
| ROCE % | - | -71.9% | -20.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 9.72% | 8.45M | $403.65M |
| 2 | Wellington Management Group, LLP | 9.04% | 7.86M | $375.75M |
| 3 | Blackrock Inc. | 5.98% | 5.20M | $248.35M |
| 4 | FMR, LLC | 5.54% | 4.82M | $230.34M |
| 5 | Vanguard Portfolio Management LLC | 4.12% | 3.58M | $171.26M |
| 6 | BAMCO Inc. | 3.71% | 3.23M | $154.10M |
| 7 | Vanguard Capital Management LLC | 3.17% | 2.75M | $131.55M |
| 8 | Jupiter Topco LLC | 2.78% | 2.42M | $115.60M |
| 9 | Invesco Ltd. | 2.64% | 2.30M | $109.83M |
| 10 | Alliancebernstein L.P. | 2.21% | 1.92M | $91.94M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HTFL
Analysts Are Bullish on Heartflow (HTFL) Stock. Here’s Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQa21HLXk5QndyY1A4allFYmdzckJwMEs5LUxxVHNLNk04TDV1X21zd1ROTURZSUFFLXpKYU9NTDlIV3hWb1pnek5zUHNZMnUtYkhuSndraDNnaTFKeDVDdi1ZV3dMZE9VeHVuZllJa1dQU1hxb1lnNTVhY1gxWDEyYjN3LVB4NzM2MXlfMn…
Insider Sale: Chief Financial Officer of $HTFL Sells 5,876 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNaFRpajczdEVManpTeEFSLUIwdnFxb3ZLeTN1ZWdvMkNBeWlQXzNqZm1kRXMwLWx3RXJuSWFuczZOWnlJMGpsc051T2xMOTFDVUI4Z1UxaEhQRmd3M2J5SWxBVGNrOGRnN1RSMnphSHRaZGFzem53MG1CNWQzOVBlZW9XN3FRQ2Y0dmZ0N3…
Heartflow (NASDAQ: HTFL) officer plans million-dollar stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPZktTb3Nyb29WeC1wU1A3RlVfcUFsVGZJOXdCM0xPMDhabmhxX2hxNVc1Zk81UVU0dU1DV0oxWUZpb2tkZE84SXhTcXZKQmtKb0xDRllJOWw2b2dnaHlaV0dNa0R2empDSFpoMjh2REVXODBmNXJEeG1kNUh6cnFseTM2SnNHMkdwVWl0UW…
HeartFlow (HTFL) Stock Rally Meets Widening Losses And Premium Valuation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPTmhzZlhwVUhrN04zMzN4dlpyanlNS3ZZLUxDOHgxMnZTTUN6QUw2aUhtbHFESThtdktLMHlYS0NsWV9aWFUzcEFzUnFETDNxblJmdWNyQjg4czBDLWtialhXSVB3a05JS2VLeGo2MkhBRDRlM2k5UTl3Z25oSmZ2LXhzQVhOVmdLdjdINU…
HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOZy11VEEyUGNNbkFNcHo5SjJBaElJWHBKSUl6c1piUlFDR2ZmbUZPVDlMVEFLcHZLS3E5RV9ZM2JLMnZyZTRtN2REeUllbzB4WTE2X2tLOFBicTlmdE9PTUVjNTJOaFV4anJ3YWJ4NWhqbkl1OF9aVE91SGNmdXRZZ3BUelYtSk1qM185QW…
HeartFlow (HTFL) Stock Rally Meets Widening Losses And Premium Valuation - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1NWUxURWdkd2JyQzJYZ0NvRDNFTktDdk5SdlpxeEhnM2l5UzF4aUxwRmRvN2Jja0tiU3Q1RU1fTWpJZllzUmRuQzViX3FpMm9RU3F0STRXSmg?oc=5" target="_blank">HeartFlow (HTFL) Stock Rally Meets Widening Loss…
HTFL — Frequently Asked Questions
What is the current share price of Heartflow, Inc. (HTFL)?
As of 2026-09-07 16:24 PDT, Heartflow, Inc. (HTFL) trades at $48.91 on NasdaqGS. Its 52-week range is $20.49 to $50.43.
What is the market capitalisation of HTFL?
Heartflow, Inc. (HTFL) has a market capitalisation of $4.22B on NasdaqGS.
What is the P/E ratio of HTFL?
HTFL trades at a trailing price-to-earnings (P/E) ratio of -15.83. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.69.
What is the return on equity (ROE) of HTFL?
HTFL has a return on equity (ROE) of -135.31%. Its return on capital employed (ROCE) is -20.20%.
Is HTFL a good stock to buy?
This page provides a data-driven analysis of Heartflow, Inc. (HTFL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.